Financial
Bailador Technology Investments logs profit of $6.9M in FY26
Bailador Technology Investments (ASX:BTI) posted a net profit after tax of $6.9 million for the financial year ended June 30.
Brie Carter
TV Presenter & Finance EditorTV presenter and finance editor at Grafa, with a Master’s in Commerce from UWA and diverse industry experience in finance, insurance, and media.
Contact
Contact editorial teamArticles by Brie Carter
Cryptocurrency
ASX company faces lawsuit over blockchain project
An ASX-listed company is facing a shareholder lawsuit over losses linked to a failed blockchain-based chess project.
Cryptocurrency
HashKey starts beta rollout of Hong Kong stablecoin
HashKey has started the beta distribution of its Hong Kong dollar stablecoin, HKDAP, under Hong Kong’s regulated digital asset framework.
Mining
Rio Tinto secures $2.5B Tomago net smelter deal
Rio Tinto (ASX:RIO) and government authorities executed an agreement to deliver a $2.5 billion, 10-year funding package for the Tomago aluminium smelter.
Cryptocurrency
Bank of England tests stablecoin payment integration
The Bank of England is testing how stablecoins could work with a digital pound in cross-border payment systems.
Retail
Treasury Wine Estates swings to $1.07B net loss in FY26
Treasury Wine Estates (ASX:TWE) reported an $1.08 billion FY26 net loss driven by United States asset impairments.
Cryptocurrency
Hawaii crypto ATM ban starts in October
Hawaii will ban cryptocurrency ATMs from 1 October under a new law that targets crypto scams.
Health
STAAR Surgical revenue more than doubles to $93.5 million
STAAR Surgical (NASDAQ:STAA) reported second-quarter 2026 net sales of $93.5 million, up 111% year over year, while net income improved to $8.1 million from a $16.8 million loss a year earlier.
Technology
Neonode revenue falls 20% to $0.5 million
Neonode (NASDAQ:NEON) reported second-quarter 2026 revenue from continuing operations of $0.5 million, down 20.4% year-over-year, with license revenue increasing to $0.4 million.
Health
Eloxx cash reaches $62 million after offering
Eloxx Pharmaceuticals (NASDAQ:ELOX) reported second-quarter 2026 results after completing a public offering that generated $66 million in gross proceeds and increased cash reserves to $62 million.